Generic Name and Formulations:
Cholestyramine resin (as Cl) 4g; per 9g packet or scoop.
Various generic manufacturers
Indications for Cholestyramine:
Hypercholesterolemia alone or with hypertriglyceridemia resistant to dietary management. Reduction in risk of coronary heart disease. Pruritus due to partial biliary obstruction.
Initially 1 packet or scoop mixed with fluid or food 1–2 times daily. Maintenance: 2–4 packets or scoops divided into 2 doses; max 6 packets or scoops daily. Increase at 4 week intervals.
See full labeling.
Complete biliary obstruction.
Obtain baseline serum cholesterol, LDL-C, and triglycerides, and monitor during therapy. May need Vit. A, D, K, and folic acid supplementation with long-term therapy. Exclude secondary causes of hypercholesterolemia (e.g., hypothyroidism, diabetes, nephrotic syndrome, dysproteinemias, obstructive liver disease, alcoholism). Favorable trend in cholesterol reduction usually occurs within 1 month; continue therapy to sustain reduction. Phenylketonuria (Light formulation). Constipation. Hemorrhoids. Pregnancy. Nursing mothers.
Bile acid sequestrant.
Inhibits absorption of phenylbutazone, warfarin, chlorothiazide, propranolol, tetracycline, penicillin G, phenobarbital, thyroid drugs, digitalis, many others; give other drugs 1–2 hours before or 4–6 hours after. Additive effects with HMG-CoA reductase inhibitors, nicotinic acid.
Constipation, fecal impaction, aggravation of hemorrhoids, GI disturbances, osteoporosis, Vit. A, D, K, or folic acid deficiencies, increased bleeding, hyperchloremic acidosis, rash, oral or anal irritation.
Formerly known under the brand name Questran.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Managing Immune-Related Adverse Events
- PD-1/PD-L1 Inhibitors May Increase the Risk of Hyperprogressive Disease in NSCLC
- Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy
- Predicting Response to Immunotherapy in Late-Stage Melanoma
- Genetic Counseling Recommended for Advanced Prostate Cancer
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Transplant Status May Affect CAR-T Therapy Outcomes in CLL and B-ALL
- Study Zeroes in on Cause of Castration-Resistant Prostate Cancer
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline